Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Adrian BagustJanette GreenhalghRichard Shaw Review Article 17 September 2012 Pages: 439 - 448
Methodological Concerns with Economic Evaluations of Meningococcal Vaccines Teresa L. Kauf Review Article 17 September 2012 Pages: 449 - 461
Are Cancer Drugs Less Likely to be Recommended for Listing by the Pharmaceutical Benefits Advisory Committee in Australia? Lesley ChimPatrick J. KellyMartin R. Stockler Original Research Article 17 September 2012 Pages: 463 - 475
Understanding the Relationship between the EQ-5D, SF-6D, HAQ and Disease Activity in Inflammatory Arthritis Roisin AdamsCathal WalshMichael Barry Original Research Article 17 September 2012 Pages: 477 - 487
Cost Effectiveness of 5-Alpha Reductase Inhibitors for the Prevention of Prostate Cancer in Multiple Patient Populations Stephanie R. EarnshawCheryl L. McDadeMichael W. Kattan Original Research Article 17 September 2012 Pages: 489 - 505
Does the Inclusion of a Cost Attribute Result in Different Preferences for the Surgical Treatment of Primary Basal Cell Carcinoma? Brigitte A. B. EssersDebby van Helvoort-PostulartCarmen D. Dirksen Original Research article 17 September 2012 Pages: 507 - 520
